Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Xintela AB
XINTXintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM that is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM, which is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. It has an agreement with Region Östergötland for GMP process development of cell therapy for burn patients. Xintela AB (publ) was incorporated in 2009 and is based in Lund, Sweden. Address: Medicon Village, Lund, Sweden, 223 81
Analytics
Objectif de Cours de WallStreet
–Ratio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés XINT
Analyse des dividendes XINT
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes XINT
Valorisation des titres XINT
financières XINT
Résultats | 2019 | Dynamique |